
Cinzia Costa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4723509/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cognitive Decline Risk Stratification in People with Late-Onset Epilepsy of Unknown Etiology: An Electroencephalographic Connectivity and Graph Theory Pilot Study. Journal of Alzheimer's Disease, 2022, 88, 893-901.	1.2	6
2	Clinical and Instrumental Characterization of Patients With Late-Onset Epilepsy. Frontiers in Neurology, 2022, 13, 851897.	1.1	4
3	Epilepsy and Alzheimer's Disease: Current Concepts and Treatment Perspective on Two Closely Related Pathologies. Current Neuropharmacology, 2022, 20, 2029-2033.	1.4	4
4	Developmental impaired Akt signaling in the Shank1 and Shank3 double knock-out mice. Molecular Psychiatry, 2021, 26, 1928-1944.	4.1	26
5	Sleep disorders and late-onset epilepsy of unknown origin: Understanding new trajectories to brain amyloidopathy. Mechanisms of Ageing and Development, 2021, 194, 111434.	2.2	11
6	Temporal lobe dysfunction in late-onset epilepsy of unknown origin. Epilepsy and Behavior, 2021, 117, 107839.	0.9	6
7	Italian cohort of Lafora disease: Clinical features, disease evolution, and genotype-phenotype correlations. Journal of the Neurological Sciences, 2021, 424, 117409.	0.3	11
8	Amyloid-β: a potential link between epilepsy and cognitive decline. Nature Reviews Neurology, 2021, 17, 469-485.	4.9	60
9	An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?. International Journal of Molecular Sciences, 2021, 22, 5991.	1.8	28
10	CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors. Neurobiology of Disease, 2021, 158, 105473.	2.1	8
11	Incidence and Antiseizure Medications of Post-stroke Epilepsy in Umbria: A Population-Based Study Using Healthcare Administrative Databases. Frontiers in Neurology, 2021, 12, 800524.	1.1	3
12	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. Cell Reports, 2021, 37, 110094.	2.9	38
13	Rivaroxaban Plasma Levels and Levetiracetam. Annals of Internal Medicine, 2020, 173, 772.	2.0	2
14	Rivaroxaban Plasma Levels and Levetiracetam: A Case Report. Annals of Internal Medicine, 2020, 173, 71-72.	2.0	20
15	Effect of Brivaracetam on Efficacy and Tolerability in Patients With Brain Tumor-Related Epilepsy: A Retrospective Multicenter Study. Frontiers in Neurology, 2020, 11, 813.	1.1	19
16	Lateâ€onset epilepsy with unknown etiology: A pilot study on neuropsychological profile, cerebrospinal fluid biomarkers, and quantitative EEG characteristics. Alzheimer's and Dementia, 2020, 16, e045129.	0.4	0
17	Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics. Frontiers in Neurology, 2020, 11, 199.	1.1	24
18	Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. Neurobiology of Disease, 2020, 140, 104848.	2.1	19

#	Article	IF	CITATIONS
19	Management of epilepsy in brain tumors. Neurological Sciences, 2019, 40, 2217-2234.	0.9	33
20	Hippocampal epileptogenesis in autoimmune encephalitis. Annals of Clinical and Translational Neurology, 2019, 6, 2261-2269.	1.7	20
21	An Italian multicentre study of perampanel in progressive myoclonus epilepsies. Epilepsy Research, 2019, 156, 106191.	0.8	19
22	Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events. Journal of Neurology, 2019, 266, 2273-2276.	1.8	4
23	Epilepsy, headache, and chronic pain. , 2019, , 187-205.		Ο
24	HCN ion channels and accessory proteins in epilepsy: genetic analysis of a large cohort of patients and review of the literature. Epilepsy Research, 2019, 153, 49-58.	0.8	32
25	Differential effect of FHM2 mutation on synaptic plasticity in distinct hippocampal regions. Cephalalgia, 2019, 39, 1333-1338.	1.8	8
26	Striatal spreading depolarization: Possible implication in levodopaâ€induced dyskineticâ€like behavior. Movement Disorders, 2019, 34, 832-844.	2.2	6
27	Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study. Epilepsy and Behavior, 2019, 101, 106592.	0.9	21
28	Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. Neurobiology of Aging, 2019, 73, 61-67.	1.5	75
29	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	1.2	34
30	Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. Current Neuropharmacology, 2019, 17, 926-946.	1.4	190
31	Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis. Neurobiology of Disease, 2018, 113, 97-108.	2.1	27
32	Lacosamide protects striatal and hippocampal neurons from inÂvitro ischemia without altering physiological synaptic plasticity. Neuropharmacology, 2018, 135, 424-430.	2.0	13
33	Liverpool Adverse Events Profile: Italian validation and predictive value for dropout from antiepileptic treatment in people with epilepsy. Epilepsy and Behavior, 2018, 81, 111-114.	0.9	10
34	Epilepsy in hemiplegic migraine: Genetic mutations and clinical implications. Cephalalgia, 2018, 38, 361-373.	1.8	36
35	Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?. Cephalalgia, 2018, 38, 274-282.	1.8	19
36	A novel de novo HCN1 loss-of-function mutation in genetic generalized epilepsy causing increased neuronal excitability. Neurobiology of Disease, 2018, 118, 55-63.	2.1	47

#	Article	IF	CITATIONS
37	Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature. International Journal of Molecular Sciences, 2018, 19, 345.	1.8	7
38	A Loss-of-Function HCN4 Mutation Associated With Familial Benign Myoclonic Epilepsy in Infancy Causes Increased Neuronal Excitability. Frontiers in Molecular Neuroscience, 2018, 11, 269.	1.4	25
39	Late onset epilepsy and Alzheimer's disease: exploring the dual pathogenic role of amyloid-β. Brain, 2018, 141, e60-e60.	3.7	12
40	Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease. Neurobiology of Disease, 2018, 118, 1-8.	2.1	22
41	Neuropsychiatric adverse events of antiepileptic drugs in brain tumourâ€related epilepsy: an Italian multicentre prospective observational study. European Journal of Neurology, 2017, 24, 1283-1289.	1.7	30
42	Clinical features and outcome of 6 new patients carrying de novo <i>KCNB1</i> gene mutations. Neurology: Genetics, 2017, 3, e206.	0.9	53
43	Epilepsy Comorbidity. Headache, 2017, , 41-63.	0.2	0
44	Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center. PLoS ONE, 2017, 12, e0180470.	1.1	23
45	Epilepsy, amyloid-β, and D1 dopamine receptors: a possible pathogenetic link?. Neurobiology of Aging, 2016, 48, 161-171.	1.5	71
46	Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. Scientific Reports, 2016, 6, 20926.	1.6	68
47	Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. Journal of Neuro-Oncology, 2016, 129, 355-361.	1.4	25
48	Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N -Methyl-D-Aspartate Receptor Subunit. Biological Psychiatry, 2016, 79, 402-414.	0.7	77
49	Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs. Neurochemical Research, 2016, 41, 340-352.	1.6	14
50	Migraine and epilepsy: what value today?. Journal of Headache and Pain, 2015, 16, A44.	2.5	2
51	O064. Antiepileptic drugs in migraine and epilepsy disorders: who is at increased risk of adverse events?. Journal of Headache and Pain, 2015, 16, A69.	2.5	0
52	Endogenous 17β-estradiol is required for activity-dependent long-term potentiation in the striatum: interaction with the dopaminergic system. Frontiers in Cellular Neuroscience, 2015, 9, 192.	1.8	43
53	Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 123-133.	1.5	30
54	A novel ATP1A2 gene mutation in familial hemiplegic migraine and epilepsy. Cephalalgia, 2014, 34, 68-72.	1.8	28

#	Article	IF	CITATIONS
55	Brain arteriovenous malformations and seizures: an Italian study. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 284-288.	0.9	44
56	Environmental enrichment restores CA1 hippocampal LTP and reduces severity of seizures in epileptic mice. Experimental Neurology, 2014, 261, 320-327.	2.0	25
57	Cortical spreading depression as a target for anti-migraine agents. Journal of Headache and Pain, 2013, 14, 62.	2.5	110
58	Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiology of Disease, 2013, 52, 229-236.	2.1	155
59	Ischemic-LTP in Striatal Spiny Neurons of both Direct and Indirect Pathway Requires the Activation of D1-Like Receptors and NO/Soluble Guanylate Cyclase/cGMP Transmission. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 278-286.	2.4	13
60	Protective Effects of Zonisamide Against Rotenone-Induced Neurotoxicity. Neurochemical Research, 2013, 38, 2631-2639.	1.6	17
61	Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18985-18990.	3.3	113
62	Mechanisms underlying altered striatal synaptic plasticity in old A53T-α synuclein overexpressing mice. Neurobiology of Aging, 2012, 33, 1792-1799.	1.5	37
63	A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation. PLoS ONE, 2012, 7, e38312.	1.1	18
64	Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain, 2012, 135, 1884-1899.	3.7	124
65	Striatum–hippocampus balance: From physiological behavior to interneuronal pathology. Progress in Neurobiology, 2011, 94, 102-114.	2.8	43
66	Neural 17β-estradiol facilitates long-term potentiation in the hippocampal CA1 region. Neuroscience, 2011, 192, 67-73.	1.1	50
67	A critical role of NO/cGMP/PKG dependent pathway in hippocampal post-ischemic LTP: Modulation by zonisamide. Neurobiology of Disease, 2011, 44, 185-191.	2.1	23
68	c-Jun N-terminal Kinase Regulates Soluble AÎ ² Oligomers and Cognitive Impairment in AD Mouse Model. Journal of Biological Chemistry, 2011, 286, 43871-43880.	1.6	74
69	Occipital arteriovenous malformations and migraine. Cephalalgia, 2011, 31, 1320-1324.	1.8	25
70	The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D ₂ /A _{2A} Receptor Interaction in the Striatum: Implications for Parkinson's Disease. Journal of Neuroscience, 2011, 31, 1850-1862.	1.7	140
71	Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia, 2010, 51, 274-279.	2.6	84
72	Impaired Plasticity at Specific Subset of Striatal Synapses in the Ts65Dn Mouse Model of Down Syndrome. Biological Psychiatry, 2010, 67, 666-671.	0.7	28

#	Article	IF	CITATIONS
73	Hippocampal Synaptic Plasticity, Memory, and Epilepsy: Effects of Long-Term Valproic Acid Treatment. Biological Psychiatry, 2010, 67, 567-574.	0.7	68
74	Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. Experimental Neurology, 2010, 221, 217-224.	2.0	28
75	Decreased NR2B Subunit Synaptic Levels Cause Impaired Long-Term Potentiation But Not Long-Term Depression. Journal of Neuroscience, 2009, 29, 669-677.	1.7	126
76	Obsessiveâ€Compulsive Disorder and Migraine With Medicationâ€Overuse Headache. Headache, 2009, 49, 1005-1013.	1.8	56
77	A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. Experimental Neurology, 2009, 217, 231-234.	2.0	19
78	Rapid effect of levetiracetam in a case of juvenile myoclonic epilepsy. Epilepsy and Behavior, 2009, 14, 269-270.	0.9	4
79	Hyperhomocysteinemia and retinal vascular changes in patients with epilepsy. Epilepsy Research, 2008, 81, 86-89.	0.8	5
80	Levetiracetam in newly diagnosed late-onset post-stroke seizures: A prospective observational study. Epilepsy Research, 2008, 82, 223-226.	0.8	62
81	A ¹ H magnetic resonance spectroscopy study in patients with obstructive sleep apnea. European Journal of Neurology, 2008, 15, 1058-1064.	1.7	34
82	Antiepileptic Drugs on Calcium Currents Recorded from Cortical and PAG Neurons: Therapeutic Implications for Migraine. Cephalalgia, 2008, 28, 1315-1326.	1.8	37
83	Polymyography in the diagnosis of childhood onset movement disorders. European Journal of Paediatric Neurology, 2008, 12, 480-483.	0.7	11
84	Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiology of Disease, 2008, 30, 186-189.	2.1	71
85	Plasticity and repair in the post-ischemic brain. Neuropharmacology, 2008, 55, 353-362.	2.0	132
86	Levetiracetam-associated hyponatremia. Seizure: the Journal of the British Epilepsy Association, 2008, 17, 389-390.	0.9	21
87	Electrophysiology and Pharmacology of Striatal Neuronal Dysfunction Induced by Mitochondrial Complex I Inhibition. Journal of Neuroscience, 2008, 28, 8040-8052.	1.7	54
88	Na + /Ca 2+ Exchanger Maintains Ionic Homeostasis in the Peri-Infarct Area. Stroke, 2007, 38, 1614-1620.	1.0	11
89	Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology, 2007, 53, 783-789.	2.0	53
90	Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid. Experimental Neurology, 2007, 207, 218-226.	2.0	32

#	Article	IF	CITATIONS
91	Levetiracetam monotherapy in Alzheimer patients with lateâ€onset seizures: a prospective observational study. European Journal of Neurology, 2007, 14, 1176-1178.	1.7	81
92	Chronic Cocaine Prevents Depotentiation at Corticostriatal Synapses. Biological Psychiatry, 2006, 60, 436-443.	0.7	43
93	Distinct roles for spinophilin and neurabin in dopamine-mediated plasticity. Neuroscience, 2006, 140, 897-911.	1.1	84
94	Tiagabine and vigabatrin reduce the severity of NMDA-induced excitotoxicity in chick retina. Experimental Brain Research, 2006, 171, 511-515.	0.7	6
95	Pathways of neurodegeneration and experimental models of basal ganglia disorders: Downstream effects of mitochondrial inhibition. European Journal of Pharmacology, 2006, 545, 65-72.	1.7	22
96	Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: Role of Na+/K+ ATPase. Neurobiology of Disease, 2006, 23, 54-60.	2.1	51
97	Multiple Mechanisms Underlying the Neuroprotective Effects of Antiepileptic Drugs Against In Vitro Ischemia. Stroke, 2006, 37, 1319-1326.	1.0	95
98	Nigrostriatal Dopaminergic Deficits and Hypokinesia Caused by Inactivation of the Familial Parkinsonism-Linked Gene DJ-1. Neuron, 2005, 45, 489-496.	3.8	485
99	Chronic Haloperidol Promotes Corticostriatal Long-Term Potentiation by Targeting Dopamine D2L Receptors. Journal of Neuroscience, 2004, 24, 8214-8222.	1.7	90
100	Coactivation of GABA A and GABA B Receptor Results in Neuroprotection During In Vitro Ischemia. Stroke, 2004, 35, 596-600.	1.0	89
101	Intracellular Calcium Increase in Epileptiform Activity: Modulation by Levetiracetam and Lamotrigine. Epilepsia, 2004, 45, 719-728.	2.6	124
102	Levetiracetam protects against kainic acid-induced toxicity. Life Sciences, 2004, 74, 1253-1264.	2.0	61
103	The Concept of "Neuroprotection" in Neurological Diseases. Current Neuropharmacology, 2004, 2, 261-263.	1.4	0
104	Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study. Experimental Neurology, 2003, 182, 461-469.	2.0	18
105	Corticostriatal LTP requires combined mGluR1 and mGluR5 activation. Neuropharmacology, 2003, 44, 8-16.	2.0	86
106	lonotropic glutamate receptors: still a target for neuroprotection in brain ischemia? insights from in vitro studies. Neurobiology of Disease, 2003, 12, 82-88.	2.1	40
107	Identification of amoebae in the CSF in a patient with meningoencephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1445-a-1446.	0.9	6
108	Effects of Psychotropic Drugs on Seizure Threshold. Drug Safety, 2002, 25, 91-110.	1.4	301